- Report
- March 2024
- 188 Pages
Global
From €3237EUR$3,374USD£2,781GBP
€3596EUR$3,749USD£3,090GBP
- Report
- November 2023
- 144 Pages
Global
From €2397EUR$2,499USD£2,059GBP
- Report
- May 2024
- 182 Pages
Global
From €4748EUR$4,950USD£4,079GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1439EUR$1,500USD£1,236GBP
- Report
- November 2023
- 175 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Report
- November 2023
- 250 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Report
- November 2023
- 183 Pages
Global
From €4701EUR$4,900USD£4,038GBP
- Report
- February 2021
- 154 Pages
Global
From €4748EUR$4,950USD£4,079GBP
- Report
- January 2022
- 60 Pages
Global
From €3789EUR$3,950USD£3,255GBP
- Report
- May 2024
- 200 Pages
From €3981EUR$4,150USD£3,420GBP
- Report
- August 2022
United States
From €1861EUR$1,940USD£1,599GBP
- Report
- August 2022
Global
From €758EUR$790USD£651GBP
- Report
- August 2021
Global
From €3828EUR$3,990USD£3,288GBP
- Report
- August 2021
Europe
From €3281EUR$3,420USD£2,818GBP
- Report
- February 2021
Global
From €2839EUR$2,960USD£2,439GBP
- Report
- November 2022
- 629 Pages
Global
From €2398EUR$2,500USD£2,060GBP
- Clinical Trials
- February 2020
- 498 Pages
Global
From €2398EUR$2,500USD£2,060GBP
- Clinical Trials
- January 2020
- 498 Pages
Global
From €2398EUR$2,500USD£2,060GBP
- Report
- February 2022
- 167 Pages
Global
From €3453EUR$3,600USD£2,967GBP
- Report
- February 2022
- 77 Pages
Middle East, Africa
From €1439EUR$1,500USD£1,236GBP
Benign Prostatic Hyperplasia (BPH) is a condition that affects the prostate gland in men. It is characterized by an enlarged prostate, which can cause urinary symptoms such as difficulty starting or stopping the flow of urine, a weak or interrupted urine stream, and a feeling of incomplete bladder emptying. BPH is not cancerous, but it can lead to an increased risk of developing prostate cancer.
The BPH drug market is composed of a variety of medications used to treat the symptoms of BPH. These medications include alpha-blockers, 5-alpha reductase inhibitors, and anticholinergics. Alpha-blockers work by relaxing the muscles of the bladder neck and prostate, allowing for improved urine flow. 5-alpha reductase inhibitors reduce the size of the prostate, while anticholinergics reduce bladder contractions.
The BPH drug market is a subset of the larger prostate cancer drug market. Prostate cancer drugs are used to treat prostate cancer, which is the second most common cancer in men. These drugs include hormone therapy, chemotherapy, and immunotherapy.
Some companies in the BPH drug market include Allergan, Astellas Pharma, and GlaxoSmithKline. Show Less Read more